Last deal

$25M

Amount

Post-IPO Equity

Stage

11.12.2023

Date

3

all rounds

$147M

Total amount

date founded

Financing round

General

About Company
Prelude Therapeutics develops novel therapies to target key drivers of cancer cell growth, survival, and resistance.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2016

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's pipeline includes four candidates currently in clinical development, which are highly differentiated, potentially best-in-class and first-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with high unmet need. Their offerings include developing orally bioavailable, small-molecule therapies to target critical intervention points in pathways of resistance to overcome treatment failure in cancer, providing hope to people with cancer.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
G1 Therapeutics

G1 Therapeutics

G1 Therapeutics is a clinical-stage company developing novel cancer therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Durham, NC, USA

total rounds

10

total raised

$697.37M
WM Therapeutics

WM Therapeutics

WM Therapeutics discovers and develops novel cancer therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Heidelberg, Germany

total rounds

1
Harpoon Therapeutics

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing T cell engagers to treat cancer and other diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

South San Francisco, CA, USA

total rounds

5

total raised

$255M
Psioxus Therapeutics

Psioxus Therapeutics

Akamis is a clinical-stage oncology company developing tumor-targeted therapeutics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Abingdon, UK

total rounds

9

total raised

$95.4M

Financials

Funding Rounds
4
3

Number of Funding Rounds

$147M

Money Raised

Their latest funding was raised on 11.12.2023. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
Fidelity Management and Research Company

Fidelity Management and Research Company

Fidelity Management and Research Company is a private investment manager that aims to make financial expertise accessible to everyone.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Boston, MA, USA

count Of Investments

259

count Of Exists

25
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

561

count Of Exists

82
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

561

count Of Exists

82
Co-Investors
Investors
2
2

Number of lead investors

2

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Series B, Series C
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

561

count Of Exists

82
Fidelity Management and Research Company

Fidelity Management and Research Company

Fidelity Management and Research Company is a private investment manager that aims to make financial expertise accessible to everyone.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Boston, MA, USA

count Of Investments

259

count Of Exists

25

People

Founders
1
Krishna Vaddi
Krishna Vaddi

Krishna Vaddi

Kris Vaddi, Ph.D. founded Prelude and served as the chief executive officer and member of the board of directors since 2016. Previously, Kris had a 12-year career at Incyte starting as a founding scientist and an executive director in 2002 and most recently as a group vice president. Kris initiated and championed JAK research programs at Incyte that led to the discovery, development and approval of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia Vera and Olumiant® (Baricitinib) for rheumatoid arthritis. Kris received his Doctorate in Veterinary Medicine from APAU in India and his Ph.D. from University of Florida.

current job

Prelude Therapeutics
Prelude Therapeutics

organization founded

1

Krishna Vaddi

Employee Profiles
13
Laurent Chardonnet

Laurent Chardonnet

Chief Financial Officer

Christopher Pierce

Executive vice president, chief of business operations

Victor Sandor

Victor Sandor

Independent Director

Dave Rominger

Director nonclinical development

Diane Heiser

Diane Heiser

Executive Director, Translational Medicine

Caroline Kelley

Senior manager, human resources

David Mauro

David Mauro

Chief Medical Officer

Adam Shilling

Vice president early development and regulatory affairs

Activity

Recent News
4
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month